U.S. Dermatology Drugs Market is Growing With the Rate of 8.2% in the Forecast Period of 2020 to 2027

U.S. Dermatology Drugs Market is forecasted to grow at 8.2% with factors such as rising prevalence of skin diseases in the U.S. and rising spending on healthcare impacted in the growth of the U.S. dermatology drugs market.

Increasing prevalence of skin diseases is propelling the demand of the market. However, high cost of dermatology drugs hampers the demand of the market.

U.S. Dermatology Drugs Market Scenario

According to Data Bridge Market Research for dermatology drugs, AbbVie Inc. accounts an estimated market share of approximately 20% to 30% in the U.S. sales revenue of AbbVie Inc., which has increased by 2.1% to generate sales revenue of USD 33,441.09 million in 2019 as compared to 2018.

In 2019, AbbVie Inc. received approval for the commercialization of their product SKYRIZI which was used in the treatment of generalized pustular psoriasis, plaque psoriasis, erythrodermic psoriasis and psoriatic arthritis in Japan.

Trends Impacting the Market

The U.S. dermatology drugs market is becoming more competitive every year with companies like AbbVie Inc. and Johnson & Johnson Services, Inc., the market leaders for dermatology drugs. The data bridge market research new reports highlight the major growth factors and opportunities in the U.S. dermatology drugs market.

For more analysis on the U.S. dermatology drugs market request for a briefing with our analysts https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=us-dermatology-drugs-market

U.S. Dermatology Drugs Market Developments & Approvals

In May 2019, Mayne Pharma Group Limited announced that they have received the approval from FDA for their drug SORILUX (calcipotriene) Foam, 0.005% in adolescents. The drug can treat plaque psoriasis of the scalp and body in patients aged 12 years and older. This drug helps in treating the most occurred disease of the region and in return will strengthens its expansion in dermatology and generate more revenue from this business segment in future.

In June 2017, MELINTA THERAPEUTICS, INC. - THE ANTIBIOTICS COMPANY announced that they have received FDA approval for its drug Baxdela which is used to treat acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria. The company commercialize their product in the market after receiving this approval.

Scope of the U.S. Dermatology Drug Market

All country based analysis of the U.S. dermatology drugs market is further analyzed based on maximum granularity into further segmentation. On the basis of drug class, the market is segmented into corticosteroids, retinoids, monoclonal antibodies, antibiotics agent, antiviral agents, antifungal drugs, antihistamines agents, immunosuppressive drugs and others. On the basis of drug type, the market is segmented into branded and generics. On the basis of prescription mode, the market is segmented into prescription based drugs and over-the-counter drugs. On the basis of indication, the market is segmented into infectious skin disease, inflammatory/autoimmune disorders, pigmentation disorders, skin cancer and others. On the basis of route of administration, the market is segmented into oral, topical and parenteral. On the basis of end user, the market is segmented into homecare, hospitals, dermatalogy clinics and others. On the basis of distribution channel, the market is segmented into retail pharmacy, hospitals pharmacy, online pharmacy and others.

To know more about the study https://www.databridgemarketresearch.com/reports/us-dermatology-drugs-market

Key Pointers Covered in the U.S. Dermatology Drugs Market Industry Trends and Forecast to 2027

Market Size

Market Regulatory Scenario

Market Shares in Different Regions

Recent Developments for Market Competitors

Recent Market Value for Different Regions

Market key Vendors and Disruptors Study

Key Market Competitors Covered in the report

Novartis AG

Pfizer Inc.

Eli Lilly and Company.

Johnson & Johnson Services, Inc.

Almirall, S.A

Mylan N.V.

Sun Pharmaceutical Industries Ltd.

UCB S.A. Belgium

Glenmark Pharmaceuticals Limited

Tolmar Pharmaceuticals, Inc.

GlaxoSmithKline plc.

Galderma Laboratories, L.P.

Teva Pharmaceutical Industries Ltd.

LEO Pharma A/S

Melinta Therapeutics, INC. - THE Antibiotics Company

Mayne Pharma Group Limited

Biofrontera AG

AbbVie Inc.

Above are the key players covered in the report, to know about more and exhaustive list of dermatology drugs contact us https://www.databridgemarketresearch.com/toc/?dbmr=us-dermatology-drugs-market

Research Methodology: U.S. Dermatology Drugs Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

Demand Side: Manufacturers, Distributors, Industrial Professionals.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Related Reports